• Dansk
  • NL
  • EN
  • FI
  • FR
  • DE
  • EL
  • IT
  • NO
  • PL
  • PT
  • RO
  • SL
  • ES
  • SV

Policy prescriptions: the firepower of the EU pharmaceutical lobby and implications for public health

A new report released today reveals the dramatic extent of the pharmaceutical industry's lobbying efforts towards EU decision-makers, with the industry spending an estimated 15 times more than civil society actors working on public health or access to medicines.

'Policy prescriptions: the firepower of the EU pharmaceutical lobby and implications for public health' by Corporate Europe Observatory probes the privileged access to decision-making in Brussels enjoyed by the sector and facilitated by a lobby spend of around €40 million, extensive meetings with policy-makers, and presence in advisory groups. Under-reporting and the continued avoidance by some of the EU's voluntary lobby transparency system mean that overall industry spending may be much higher than the transparency register reveals.

The report shows that Big Pharma enjoys a staggering number of meetings with European Commission departments and officials. For example, influential EU pharmaceutical trade association, the European Federation of Pharmaceutical Industries and Associations (EFPIA), had over 50 meetings with the Juncker Commission in its first four and a half months of office.

The study examines some of Big Pharma’s channels of influence in the EU and exposes concrete examples of EU law and policies that have been targeted or shaped by the industry. These include rules around clinical trials’ data transparency, trade secrets, and the negotiation of the EU-US trade deal, the Transatlantic Trade and Investment Partnership (TTIP).

It also puts pharma lobby group EFPIA in the spotlight, examining its goals, tactics, access and influence, including a critique of the EU’s multi-billion euro public-private partnership with EFPIA, the ‘Innovative Medicines Initiative’.

Report: http://corporateeurope.org/sites/default/files/20150904_bigpharma_web.pdf

 

Help!

Exposing the lobbying of big business costs money. Would you consider a donation to help us continue? We refuse funding from the EU, governments, political parties and corporations to be as independent as possible, so every single donation really helps. Thanks!

 

 

 

Add new comment

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Get our monthly newsletter

Follow us on social media

Lobbying around the EU Copyright Directive has been intense: big-budget tech platforms led by Google as well as tech industry trade associations on one side, historically important collecting societies, the creative industries and publishers on the other. The interests and opinions of citizens have become sidelined in the resulting turmoil.

A seemingly innocent concept, the “innovation priniciple” has been invented by some of the dirtiest industries in Europe. They have carefully and strategically inserted it into the EU system, where it could have a significant impact on the shaping of new EU legislation or policies, and those under revision.

The EU institutions are currently negotiating new single market rules that could have a severe and distinctly negative impact on decision-making in parliaments, regional assemblies and city councils across Europe. Read Corporate Europe Observatory's Questions & Answers on the proposal to give the Commission new powers to annul local decisions.

As EU negotiators try to reach agreement on the single-use plastics proposal this week, industry lobbies continue their push to avoid robust obligations.

Lobby Planet 2017 banner